Biomea Fusion, Inc.
NASDAQ: BMEA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael J. Hitchcock
- Employees
- 79
- Headquarters
- Redwood City, United States
- IPO year
- 2021
- Market cap
- $74.4M
- Website
- https://biomeafusion.com
Loading BMEA…
Loading profile data…Frequently asked questions about BMEA
What does Biomea Fusion, Inc. (BMEA) do?
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covale...
Where does BMEA trade?
Biomea Fusion, Inc. (BMEA) trades on the NASDAQ Global Select.
What sector is BMEA in?
Biomea Fusion, Inc. (BMEA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Biomea Fusion, Inc.?
Michael J. Hitchcock is the chief executive officer of Biomea Fusion, Inc. (BMEA).
Where is Biomea Fusion, Inc. headquartered?
Biomea Fusion, Inc. is headquartered in United States.
Does BMEA pay a dividend?
Biomea Fusion, Inc. (BMEA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BMEA go public?
Biomea Fusion, Inc. (BMEA) completed its initial public offering in 2021.